Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues
- 1 December 2000
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 9 (12) , 2767-2782
- https://doi.org/10.1517/13543784.9.12.2767
Abstract
The fact that proteins such as Ras, Rac and RhoA require farnesylation or geranylgeranylation to induce malignant transformation prompted many investigators to develop farnesyltransferase (FTase) and geranylgeranyltransferase I (GGTase I) inhibitors (FTIs and GGTIs, respectively) as novel anticancer drugs. Although FTIs have been shown to antagonise oncogenic signalling, reverse malignant transformation, inhibit human tumour growth in nude mice and induce tumour regression in transgenic mice without any signs of toxicity, their mechanism of action is not known. This review will focus on important mechanistic issues as well as bench to bedside translational issues. These will include the relevance to cancer therapy of the alternative geranylgeranylation of K-Ras when FTase is inhibited; a thorough discussion about evidence for and against the involvement of inhibition of prenylation of Ras and RhoB in the mechanism of FTIs’ antitumour activity as well as effects of FTIs and GGTIs on the cell cycle machiner...Keywords
This publication has 32 references indexed in Scilit:
- Rho family proteins and Ras transformation: the RHOad less traveled gets congestedOncogene, 1998
- Anticancer activity of farnesyltransferase and geranylgeranyltransferase i inhibitors: prospects for drug developmentExpert Opinion on Investigational Drugs, 1997
- Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell linesOncogene, 1997
- THE POTENTIAL OF FARNESYLTRANSFERASE INHIBITORS AS CANCER CHEMOTHERAPEUTICSAnnual Review of Pharmacology and Toxicology, 1997
- Inhibition of ras prenylation: A novel approach to cancer chemotherapyPharmacology & Therapeutics, 1997
- PROTEIN PRENYLATION: Molecular Mechanisms and Functional ConsequencesAnnual Review of Biochemistry, 1996
- Disruption of Oncogenic K-Ras4B Processing and Signaling by a Potent Geranylgeranyltransferase I InhibitorPublished by Elsevier ,1995
- Peptidomimetic inhibitors of p21ras farnesyltransferase: Hydrophobic functionalization leads to disruption of p21ras membrane association in whole cellsBioorganic & Medicinal Chemistry Letters, 1994
- Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptidesCell, 1990
- ras GENESAnnual Review of Biochemistry, 1987